Sionna Therapeutics (Ticker: SION) is a clinical-stage biopharmaceutical company developing medicines for cystic fibrosis (CF) patients, that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. The company is conducting ongoing Phase 1 trials of two candidates, SION-719 and SION-451.

Sionna Therapeutics will list on February 7, 2025, on NASDAQ. The firm is selling 8.8 million shares at the price range of $16.00-$18.00. The expected Market Capitalization at offer is $692.88 million. The total offer size is $150.0 million. The offering is managed by Goldman Sachs/TD Cowen/Stifel/Guggenheim Securities.